Mabpharm Sets 2026 AGM, Seeks 10% Share Buyback Mandate

Mabpharm Limited ( (HK:2181) ) has provided an update.

Mabpharm Limited has called its annual general meeting for June 26, 2026, in Shanghai to present the audited consolidated financial statements for the year ended December 31, 2025, and the accompanying directors’ and auditors’ reports to shareholders. The agenda also includes the re-election of three executive directors and one independent non-executive director, authorization for the board to set directors’ pay, re-appointment of Ernst & Young as auditor, and approval of a general mandate allowing the company to repurchase up to 10% of its issued share capital, a move that could provide flexibility in capital management and potentially support shareholder value.

By seeking a share repurchase mandate and confirming its board and auditor arrangements, Mabpharm is signaling continuity in governance and financial oversight while preserving room to adjust its capital structure in response to market conditions. The proposed authority to buy back up to 412,408,000 shares, subject to regulatory limits, may enable the company to respond swiftly to perceived undervaluation or optimize its balance sheet, which could influence investor sentiment and the trading dynamics of its stock.

More about Mabpharm Limited

Mabpharm Limited is a biopharmaceutical company listed on the Hong Kong Stock Exchange that focuses on the research, development, and commercialization of antibody-based therapies. The company operates primarily in mainland China, leveraging its facilities in Shanghai’s Zhangjiang Hi-Tech Park to develop innovative treatments for various diseases and address unmet medical needs in domestic and international markets.

Average Trading Volume: 1,792,063

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.84B

See more data about 2181 stock on TipRanks’ Stock Analysis page.